Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(33%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_3
1
17%
Ph phase_4
1
17%
Ph not_applicable
2
33%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(1)
Other(2)

Detailed Status

Recruiting2
unknown2
Not yet recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (25.0%)
Phase 41 (25.0%)
N/A2 (50.0%)

Trials by Status

not_yet_recruiting117%
recruiting233%
unknown233%
completed117%

Recent Activity

2 active trials
Showing 5 of 6
recruitingnot_applicable

The PEERLESS II Study

NCT06055920
recruitingphase_4

Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis

NCT07352358
completed

FlowTriever All-Comer Registry for Patient Safety and Hemodynamics

NCT03761173
not_yet_recruitingphase_3

Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)

NCT06045858
unknownnot_applicable

Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF

NCT06057467
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06055920Not Applicable

The PEERLESS II Study

Recruiting
NCT07352358Phase 4

Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis

Recruiting
NCT03761173

FlowTriever All-Comer Registry for Patient Safety and Hemodynamics

Completed
NCT06045858Phase 3

Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)

Not Yet Recruiting
NCT06057467Not Applicable

Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF

Unknown
NCT04527666

Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6